Login

Financial Snapshot

Revenue
TTM
$16.57B
Gross Margin
TTM
61.91%
Net Income
TTM
$2.383B
Current Assets
2025 Q4
$4.550B
Current Liabilities
2025 Q4
$4.933B
Current Ratio
2025 Q4
92.24%
Total Assets
2025 Q4
Total Liabilities
2025 Q4
Book Value
2025 Q4
16.48B
Cash
2025 Q4
$1.324B
P/E
TTM
12.13
Free Cash Flow
TTM
$3.474B

Stock Price

Loading...
Market Cap: $28.909 Billion

About Haleon PLC

Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.

Industry: Perfumes, Cosmetics & Other Toilet Preparations Peers: ALTEROLA BIOTECH INC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support